Evidence-based treatment options for allergic diseases in otolaryngology: An update;Evidenzbasierte Therapieoptionen von Allergien im HNO-Bereich: Ein Update

HNO

Volumn 61, Issue 6, 2013, Pages 525-538

  Klimek, L ^a   Sperl, A ^a  

^a ZENTRUM FÜR RHINOLOGIE UND ALLERGOLOGIE   (Germany)

Author keywords

Allergic rhinitis; Antihistamines; Atopic dermatitis; Glucocorticoids; Immunotherapy

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

EVIDENCE BASED MEDICINE; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; OTORHINOLARYNGOLOGIC DISEASES; PROCEDURES; TREATMENT OUTCOME;

EVIDENCE-BASED MEDICINE; HUMANS; HYPERSENSITIVITY; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; OTORHINOLARYNGOLOGIC DISEASES; TREATMENT OUTCOME;

EID: 84878812729     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-013-2709-0     Document Type: Article

References (53)

1. Anolik R (2008) Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100: 264-271.
2. Bachert C, Kuna P, Sanquer F et al (2009) Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 64: 158-165.
3. Barnes PJ (2006) Corticosteroid effects on cell signalling. Eur Respir J 27: 413-426.
4. Benninger M, Farrar JR, Blaiss M et al. (2010) Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 104(1): 13-29.
5. Brozek JL, Bousquet J, Baena-Cagnani CE et al (2010) Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 126: 466-476.
6. Bussmann C, Bockenhoff A, Henke H et al (2006) Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 118: 1292-1298.
7. Canonica GW, Bousquet J, Mullol J et al (2007) A survey of the burden of allergic rhinitis in Europe. Allergy 62: 17-25.
8. Carr W, Bernstein J, Lieberman P et al (2012) A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 129: 1282-1289.
9. Cingi C, Gunhan K, Gage-White L et al (2010) Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope 120: 1718-1723.
10. Dalal AA, Stanford R, Henry H et al (2008) Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 101: 23-29.
11. Day JH, Briscoe MP, Ratz JD et al (2009) Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit. Ann Allergy Asthma Immunol 102: 328-338.
12. Deutsche Dermatologische Gesellschaft, Deutsche Gesellschaft für Allergologie und Klinische Immunologie, Deutsche Gesellschaft für Kinder- und Jugendmedizin (2008) S2-Leitlinie Dermatologie: Neurodermitis. http://www. awmf. org/leitlinien/detail/ll/013-027. html. Zugegriffen: 11. Jan. 2012.
13. Di Lorenzo G, Pacor ML, Pellitteri ME et al (2004) Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34: 259-267.
14. Edwards AM, Stevens MT, Church MK (2011) The effects of topical sodium cromoglicate on itch and flare in human skin induced by intradermal histamine: a randomised double-blind vehicle controlled intra-subject design trial. BMC Res Notes 4: 47.
15. Friedmann PS, Palmer R, Tan E et al (2007) A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin Exp Allergy 37: 1536-1540.
16. Hampel FC, Ratner PH, van Bavel J et al (2010) Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 105: 168-173.
17. Horak F, Zieglmayer UP, Zieglmayer R et al (2006) Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 22: 151-157.
18. Interdisziplinäre Arbeitsgruppe "Allergische Rhinitis" Der Sektion Hno (2003) Allergische Rhinokonjunktivitis: Leitlinie der Deutschen Gesellschaft für Allergologie und Klinische Immunologie (DGAI). Allergo J 182-194.
19. Kaliner MA, Berger WE, Ratner PH et al (2011) The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 106: S6-S11.
20. Kamin W, Kopp MV, Erdnuess F et al (2010) Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 21: e160-e165.
21. Kay GG, Quig ME (2001) Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proc 22: 281-283.
22. Kleine-Tebbe J, Bufe A, Ebner C et al (2009) Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen. Allergo J 508-537.
23. Klimek L, Högger P, Pfaar O (2012) Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis. Teil 1: Pathophysiologie, molekulare Grundlagen. HNO 60: 611-617.
24. Klimek L, Schendzielorz P, Högger P (2010) Nasale Glukokortikosteroid-Therapie: ein Update. Allergologie 34: 307-318.
25. Kopp MV, Hamelmann E, Zielen S et al (2009) Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 39: 271-279.
26. Kuna P, Bachert C, Nowacki Z et al (2009) Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 39: 1338-1347.
27. Kwok P (2009) Äußeres Ohr: Praxis der HNO-Heilkunde, Kopf- und Halschirurgie. In: Strutz J, Mann W (Hrsg) Praxis der HNO-Heilkunde, Kopf- und Halschirurgie. Thieme, Stuttgart, S 240-253.
28. Ledford DK (2009) Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther 9: 933-943.
29. Lehtimäki L, Petäys T, Haahtela T (2009) Montelukast is not effective in controlling allergic symptoms outside the airways: a randomised double-blind placebo-controlled crossover study. Int Arch Allergy Immunol 149: 150-153.
30. Leung DYM, Szefler SJ and the Associate Editors of the JACI (2012) The editors' choice. MP29-02: A major advancement in the treatment of allergic rhinitis. J Allergy Clin Immunol 129(5): 1216.
31. Matricardi PM, Kuna P, Panetta V et al (2011) Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol 128: 791-799 e796.
32. Meltzer EO, Laforce C, Ratner P et al (2012) MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 33: 324-332.
33. Mullol J, Bousquet J, Bachert C et al (2008) Rupatadine in allergic rhinitis and chronic urticaria. Allergy 63(Suppl 87): 5-28.
34. Niven R, Chung KF, Panahloo Z et al (2008) Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 102: 1371-1378.
35. Okano M (2009) Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol 158: 164-173.
36. Perez I, Villa M, De La Cruz G et al (2002) Rupatadine in allergic rhinitis: pooled analysis of efficacy data. Allergy 57: 245.
37. Prenner B, Anolik R, Danzig M et al (2009) Efficacy and safety of fixed-dose loratadine/montelukast in seasonal allergic rhinitis: effects on nasal congestion. Allergy Asthma Proc 30: 263-269.
38. Ratner PH, Ehrlich PM, Fineman SM et al (2002) Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc 77: 350-354.
39. Ratner PH, Hampel F, Bavel J van et al (2008) Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100: 74-81.
40. Rodrigo GJ, Yanez A (2006) The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 96: 779-786.
41. Sádaba Díaz De Rada B, Azanza Perea JR, Gomez-Guiu Hormigos A (2011) Bilastine for the relief of allergy symptoms. Drugs Today (Barc) 47: 251-262.
42. Samuelsson B (1983) Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568-575.
43. Schwabe U, KV Nordrhein und die Nordrheinischen Krankenkassen (2013) Patentgeschützte Analogpräparate (Me-too-Liste 2013 in der modifizierten Fassung von 2011). http://www. kvno. de/downloads/verordnungen/me_too2013. pdf. Zugegriffen: 24. Feb. 2013.
44. Sivam A, Jeswani S, Reder L et al (2010) Olfactory cleft inflammation is present in seasonal allergic rhinitis and is reduced with intranasal steroids. Am J Rhinol Allergy 24: 286-290.
45. Skoner DP, Rachelefsky GS, Meltzer EO et al (2000) Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105: E23.
46. Stock P, Rolinck-Werninghaus C, Wahn U et al (2007) The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 21: 403-410.
47. Stokes JR, Romero FA Jr, Allan RJ et al (2012) The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 129: 409-412.
48. Thorn C, Pfaar O, Hörmann K et al (2010) Rupatadin - Pharmakologie, klinische Wirksamkeit und therapeuthische Wirksamkeit eines neuen Antihistamins mit zusätzlicher PAF-antagonisierender Wirkung. Allergologie 33: 429-440.
49. Wong IY, Soh SE, Chng SY et al (2010) Compliance with topical nasal medication - an evaluation in children with rhinitis. Pediatr Allergy Immunol 21: 1146-1150.
50. Yamamoto H, Yamada T, Kubo S et al (2010) Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled study. Allergy Asthma Proc 31: 296-303.
51. Yanase DJ, David-Bajar K (2001) The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 44: 89-93.
52. Yáñez A, Rodrigo GJ (2002) Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 89: 479-484.
53. Zuberbier T, Oanta A, Bogacka E et al (2010) Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 65: 516-528.